文献速递儿科与产科急症

自我报告产前大麻使用与母亲、围产期及新生儿结局的关联

Association Between Self-reported Prenatal Cannabis Use and Maternal, Perinatal, and Neonatal Outcomes.
PubMed 文献 · JAMA · 2019-01-01
一句话结论加拿大安大略省基于人群的回顾性队列显示,孕期自我报告使用大麻与早产风险升高相关(匹配队列RR 1.41,95%CI 1.36-1.47),但可能受残余混杂限制。

该研究为加拿大安大略省2012年4月至2017年12月基于人群的回顾性队列,纳入661617名15岁及以上活产和死产孕妇,其中9427人(1.4%)自我报告孕期使用大麻。经粗化精确匹配后得到5639名报告使用者和92873名非使用者,分析显示大麻暴露与早产(<37周)风险升高相关(风险差2.98%,95%CI 2.63%-3.34%;RR 1.41,95%CI 1.36-1.47)。暴露还与小于胎龄儿(RR 1.53)、胎盘早剥(RR 1.72)、转入新生儿重症监护(RR 1.40)和5分钟Apgar评分<4(RR 1.28)相关。作者结论认为报告大麻使用与早产风险增加显著相关,但发现可能受残余混杂限制。

要点

  • 在匹配队列中,孕期报告大麻使用与早产(<37周)风险升高相关:RR 1.41(95%CI 1.36-1.47),风险差2.98%(95%CI 2.63%-3.34%)。
  • 匹配队列中,报告大麻使用与小于胎龄儿(第3百分位)频率更高相关:6.1% vs 4.0%,RR 1.53(95%CI 1.45-1.61)。
  • 匹配队列中,报告大麻使用与胎盘早剥频率更高相关:1.6% vs 0.9%,RR 1.72(95%CI 1.54-1.92)。
  • 匹配队列中,报告大麻使用与转入新生儿重症监护频率更高相关:19.3% vs 13.8%,RR 1.40(95%CI 1.36-1.44)。
  • 匹配队列中,报告大麻使用与5分钟Apgar评分<4频率更高相关:1.1% vs 0.9%,RR 1.28(95%CI 1.13-1.45)。

适用人群与场景

  • 加拿大安大略省2012年4月至2017年12月间15岁及以上、发生活产或死产的孕妇。
  • 孕期大麻暴露通过常规围产期保健中的自我报告确定。

诊断标准与关键阈值

  • 早产定义为妊娠37周前分娩;亚类包括34至36 6/7周(晚期早产)、32至33 6/7周、28至31 6/7周及小于28周(极早产)。

研究设计与关键结果

  • 研究类型为基于人群的回顾性队列,覆盖加拿大安大略省2012年4月至2017年12月活产和死产,纳入661617名孕妇,平均孕周39.3周,51%婴儿为男性,母亲平均年龄30.4岁,9427人(1.4%)报告孕期使用大麻。
  • 采用粗化精确匹配和泊松回归估计风险差(RD)与相对风险(RR);匹配后样本为5639名报告使用者和92873名非使用者。
  • 未匹配队列中,早产(<37周)粗率在未报告大麻使用者为6.1%,在报告使用者为12.0%(RD 5.88%,95%CI 5.22%-6.54%)。
  • 匹配队列中,报告大麻暴露与早产显著相关:RD 2.98%(95%CI 2.63%-3.34%),RR 1.41(95%CI 1.36-1.47)。
  • 匹配队列中,报告大麻暴露与小于胎龄儿(第3百分位)频率更高相关:6.1% vs 4.0%,RR 1.53(95%CI 1.45-1.61)。
  • 匹配队列中,报告大麻暴露与胎盘早剥频率更高相关:1.6% vs 0.9%,RR 1.72(95%CI 1.54-1.92)。
  • 匹配队列中,报告大麻暴露与转入新生儿重症监护频率更高相关:19.3% vs 13.8%,RR 1.40(95%CI 1.36-1.44)。
  • 匹配队列中,报告大麻暴露与5分钟Apgar评分<4频率更高相关:1.1% vs 0.9%,RR 1.28(95%CI 1.13-1.45)。

证据类型、等级与局限

  • 证据类型为基于人群的回顾性队列研究。
  • 局限:原文报告发现可能受残余混杂限制。

对床旁实践的改变

  • 原文结论指出,在加拿大安大略省孕妇中,报告大麻使用与早产风险增加显著相关。
  • 原文结论指出,研究发现可能受残余混杂限制。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

IMPORTANCE: Recent evidence suggests that cannabis use during pregnancy is increasing, although population-based data about perinatal outcomes following in utero exposure remain limited.

OBJECTIVE: To assess whether there are associations between self-reported prenatal cannabis use and adverse maternal and perinatal outcomes.

DESIGN, SETTING, AND PARTICIPANTS: Population-based retrospective cohort study covering live births and stillbirths among women aged 15 years and older in Ontario, Canada, between April 2012 and December 2017.

EXPOSURES: Self-reported cannabis exposure in pregnancy was ascertained through routine perinatal care.

MAIN OUTCOMES AND MEASURES: The primary outcome was preterm birth before 37 weeks' gestation. Indicators were defined for birth occurring at 34 to 36 6/7 weeks' gestation (late preterm), 32 to 33 6/7 weeks' gestation, 28 to 31 6/7 weeks' gestation, and less than 28 weeks' gestation (very preterm birth). Ten secondary outcomes were examined including small for gestational age, placental abruption, transfer to neonatal intensive care, and 5-minute Apgar score. Coarsened exact matching techniques and Poisson regression models were used to estimate the risk difference (RD) and relative risk (RR) of outcomes associated with cannabis exposure and control for confounding.

RESULTS: In a cohort of 661 617 women, the mean gestational age was 39.3 weeks and 51% of infants were male. Mothers had a mean age of 30.4 years and 9427 (1.4%) reported cannabis use during pregnancy. Imbalance in measured maternal obstetrical and sociodemographic characteristics between reported cannabis users and nonusers was attenuated using matching, yielding a sample of 5639 reported users and 92 873 nonusers. The crude rate of preterm birth less than 37 weeks' gestation was 6.1% among women who did not report cannabis use and 12.0% among those reporting use in the unmatched cohort (RD, 5.88% [95% CI, 5.22%-6.54%]). In the matched cohort, reported cannabis exposure was significantly associated with an RD of 2.98% (95% CI, 2.63%-3.34%) and an RR of 1.41 (95% CI, 1.36-1.47) for preterm birth. Compared with no reported use, cannabis exposure was significantly associated with greater frequency of small for gestational age (third percentile, 6.1% vs 4.0%; RR, 1.53 [95% CI, 1.45-1.61]), placental abruption (1.6% vs 0.9%; RR, 1.72 [95% CI, 1.54-1.92]), transfer to neonatal intensive care (19.3% vs 13.8%; RR, 1.40 [95% CI, 1.36-1.44]), and 5-minute Apgar score less than 4 (1.1% vs 0.9%; RR, 1.28 [95% CI, 1.13-1.45]).

CONCLUSIONS AND RELEVANCE: Among pregnant women in Ontario, Canada, reported cannabis use was significantly associated with an increased risk of preterm birth. Findings may be limited by residual confounding.

来源:JAMA,查看原文。版权归原作者所有。

参考来源

  1. Corsi DJ, Walsh L, Weiss D, et al. Association Between Self-reported Prenatal Cannabis Use and Maternal, Perinatal, and Neonatal Outcomes. JAMA. 2019. PMID: 31211826. doi:10.1001/jama.2019.8734

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。